PureTech Health (PRTC) Competitors

Arcutis Biotherapeutics (NASDAQ:ARQT) and PureTech Health (NASDAQ:PRTC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

Which has more volatility & risk, ARQT or PRTC?

Arcutis Biotherapeutics has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, PureTech Health has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.

Which has better valuation and earnings, ARQT or PRTC?

PureTech Health has lower revenue, but higher earnings than Arcutis Biotherapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$196.54M	8.34	-$140.04M	-$1.04	-13.22
PureTech Health	$4.83M	87.45	$27.78M	N/A	N/A

Do insiders and institutionals have more ownership in ARQT or PRTC?

0.0% of PureTech Health shares are owned by institutional investors. 9.4% of Arcutis Biotherapeutics shares are owned by company insiders. Comparatively, 5.3% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Does the media prefer ARQT or PRTC?

In the previous week, Arcutis Biotherapeutics had 3 more articles in the media than PureTech Health. MarketBeat recorded 6 mentions for Arcutis Biotherapeutics and 3 mentions for PureTech Health. Arcutis Biotherapeutics' average media sentiment score of 1.03 beat PureTech Health's score of 0.62 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PureTech Health	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer ARQT or PRTC?

Arcutis Biotherapeutics presently has a consensus target price of $18.80, suggesting a potential upside of 36.73%. PureTech Health has a consensus target price of $45.00, suggesting a potential upside of 155.90%. Given PureTech Health's stronger consensus rating and higher possible upside, analysts plainly believe PureTech Health is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
PureTech Health	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50

Is ARQT or PRTC more profitable?

PureTech Health has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -60.95%. PureTech Health's return on equity of 0.00% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-60.95%	-80.66%	-32.94%
PureTech Health	N/A	N/A	N/A

Summary

PureTech Health beats Arcutis Biotherapeutics on 9 of the 15 factors compared between the two stocks.